Table I.
Clinicopathological features of the patients.
| Feature | Group A (n=27) | Group B (n=35) | Total (n=62) |
|---|---|---|---|
| Gender [n (%)] | |||
| Female | 11 (40.74) | 12 (34.29) | 23 (37.1) |
| Male | 16 (59.26) | 23 (65.71) | 39 (62.9) |
| Age [mean (median)], in years | 63.81 (66) | 64.69 (62) | 64.30 (64.5) |
| Disease stage at start of chemotherapy [n (%)] | |||
| II | 2 (7.41) | 5 (14.29) | 7 (11.29) |
| III | 3 (11.11) | 12 (34.29) | 15 (24.19) |
| IV | 22 (81.48) | 18 (51.43) | 40 (64.52) |
| Surgery [n (%)] | |||
| None | 20 (74.07) | 20 (57.14) | 40 (64.52) |
| Palliative | 1 (3.7) | 6 (17.14) | 7 (11.29) |
| Radical | 6 (22.22) | 9 (25.71) | 15 (24.19) |
| Metastases [n (%)] | |||
| No | 5 (18.52) | 17 (48.57) | 22 (35.48) |
| Yes | 22 (81.48) | 18 (51.43) | 40 (64.52) |
| Metastatic site [n (%)] | |||
| Liver | 13 (59.09) | 7 (38.89) | 20 (50) |
| Peritoneum | 4 (18.18) | 4 (22.22) | 8 (20) |
| Lung | 2 (9.09) | 2 (11.11) | 4 (10) |
| Liver, peritoneum | 1 (4.55) | 4 (22.22) | 5 (12.5) |
| Liver, lung | 1 (4.55) | 0 (0) | 1 (12.5) |
| Lung, peritoneum | 1 (4.55) | 1 (5.56) | 2 (5) |
| Chemotherapy [n (%)] | |||
| No | 4 (14.81) | 0 (0) | 4 (6.45) |
| Yes | 23 (85.19) | 35 (100) | 58 (93.55) |
| Type of chemotherapy [n (%)] | |||
| GEM | 13 (56.52) | 15 (42.86) | 28 (48.28) |
| GEMOX | 9 (39.13) | 14 (40) | 23 (39.66) |
| BEV+CAPE+RT | 0 (0) | 6 (17.14) | 6 (10.34) |
| 5-FU+levofolinate calcium | 1 (4.35) | 0 (0) | 1 (1.72) |
| Response [n (%)] | |||
| Complete remission (CR) | 0 (0) | 0 (0) | 0 (0) |
| Partial remission (PR) | 0 (0) | 1 (2.86) | 1 (1.72) |
| Stable disease (SD) | 8 (34.78) | 22 (62.86) | 30 (51.72) |
| Disease progression (DP) | 14 (60.87) | 12 (34.29) | 26 (44.83) |
Group A, patients evaluated only on the day of admission prior to chemotherapy (time 0); group B, patients evaluated on the day of admission (time 0) (prior to chemotherapy) and at first restaging (after an interval of 2–3 months depending on the chemotherapy regime) in parallel with evaluation of the clinical course. GEM, gemcitabine; OX, oxaliplatin; BEV, bevacizumab; CAPE, capecitabine; RT, radiotherapy; 5-FU, 5-fluorouracil.